At the time of writing, Intellia Therapeutics Inc [NTLA] stock is trading at $9.61, down -1.33%. An important factor to consider is whether the stock is rising or falling in short-term value. The NTLA shares have gain 6.90% over the last week, with a monthly amount drifted -29.18%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Intellia Therapeutics Inc [NASDAQ: NTLA] stock has seen the most recent analyst activity on November 12, 2025, when Wolfe Research downgraded its rating to a Peer Perform. Previously, Evercore ISI downgraded its rating to In-line on November 11, 2025, and kept the price target unchanged to $8. On November 07, 2025, downgrade downgraded it’s rating to Underweight but maintained its price target of $5 on the stock. RBC Capital Mkts downgraded its rating to a Sector Perform but stick to its price target of $14 on October 28, 2025. Bernstein downgraded its rating to a Mkt Perform. William Blair downgraded its rating to Mkt Perform for this stock on October 27, 2025. In a note dated October 27, 2025, Guggenheim downgraded a Neutral rating on this stock.
For the past year, the stock price of Intellia Therapeutics Inc fluctuated between $5.90 and $28.25. Currently, Wall Street analysts expect the stock to reach $18.69 within the next 12 months. Intellia Therapeutics Inc [NASDAQ: NTLA] shares were valued at $9.61 at the most recent close of the market. An investor can expect a potential return of 94.48% based on the average NTLA price forecast.
Analyzing the NTLA fundamentals
According to Intellia Therapeutics Inc [NASDAQ:NTLA], the company’s sales were 57.53M for trailing twelve months, which represents an 51.27% jump. Gross Profit Margin for this corporation currently stands at 0.67% with Operating Profit Margin at -6.38%, Pretax Profit Margin comes in at -7.75%, and Net Profit Margin reading is -7.75%. To continue investigating profitability, this company’s Return on Assets is posted at -0.48, Equity is -0.57 and Total Capital is -0.44. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.43 points at the first support level, and at 9.24 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.73, and for the 2nd resistance point, it is at 9.84.
Ratios To Look Out For
It is important to note that Intellia Therapeutics Inc [NASDAQ:NTLA] has a current ratio of 6.21. On the other hand, the Quick Ratio is 6.21, and the Cash Ratio is 2.06. Considering the valuation of this stock, the price to sales ratio is 19.35, the price to book ratio is 1.49.
Transactions by insiders
Recent insider trading involved Schultes Birgit C, EVP, Chief Scientific Officer, that happened on Oct 01 ’25 when 31.0 shares were sold. VP, Chief Accounting Officer, Dube Michael P completed a deal on Oct 01 ’25 to sell 1871.0 shares. Meanwhile, Director CHASE WILLIAM J bought 100000.0 shares on Aug 20 ’25.
